These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18182978)

  • 1. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.
    Balin-Gauthier D; Delord JP; Pillaire MJ; Rochaix P; Hoffman JS; Bugat R; Cazaux C; Canal P; Allal BC
    Br J Cancer; 2008 Jan; 98(1):120-8. PubMed ID: 18182978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
    Ding X; Qu X; Fan Y; Che X; Qu J; Xu L; Liu J; Liu Y
    Anticancer Drugs; 2014 Mar; 25(3):315-22. PubMed ID: 24300914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
    Nannizzi S; Veal GJ; Giovannetti E; Mey V; Ricciardi S; Ottley CJ; Del Tacca M; Danesi R
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):547-58. PubMed ID: 20020129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines.
    Luo HY; Wei W; Shi YX; Chen XQ; Li YH; Wang F; Qiu MZ; Li FH; Yan SL; Zeng MS; Huang P; Xu RH
    Oncol Rep; 2010 Jun; 23(6):1735-45. PubMed ID: 20428833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
    Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
    Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
    Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
    Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
    J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
    Lin S; Lei K; Du W; Yang L; Shi H; Gao Y; Yin P; Liang X; Liu J
    Int J Biochem Cell Biol; 2016 Feb; 71():24-34. PubMed ID: 26673998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines.
    Li XL; Yi SQ; Xu JM; Zhang Y; Yingying-Feng ; Chen W; Song ST
    Cancer Invest; 2010 Dec; 28(10):1038-47. PubMed ID: 20590442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
    Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
    Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
    Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
    Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
    Lovejoy KS; Serova M; Bieche I; Emami S; D'Incalci M; Broggini M; Erba E; Gespach C; Cvitkovic E; Faivre S; Raymond E; Lippard SJ
    Mol Cancer Ther; 2011 Sep; 10(9):1709-19. PubMed ID: 21750216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP.
    Li JJ; Ding Y; Li DD; Peng RQ; Feng GK; Zeng YX; Zhu XF; Zhang XS
    Cancer Biol Ther; 2009 Oct; 8(20):1914-21. PubMed ID: 20009541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
    Qiu H; Yashiro M; Zhang X; Miwa A; Hirakawa K
    Cancer Lett; 2011 Aug; 307(1):47-52. PubMed ID: 21482024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.